EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders

Gwang Ha Kim iD, Dong Chan Joo, Moon Won Lee iD, Bong Eun Lee

Journal of Clinical Medicine · 11.05.2026 · 15 (10) · 3700

DOI: 10.3390/jcm15103700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.05.2026. Verfasst von Gwang Ha Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proton pump inhibitors (PPIs) serve as the primary treatment for acid-related disorders, such as gastroesophageal reflux disease and peptic ulcer disease. Although PPIs are regarded as the first-line medication for acid suppression, they have notable limitations, including the need for acid-mediated activation, a short half-life and duration of action, and metabolic variability. Zastaprazan is a newly developed potassium-competitive acid blocker (P-CAB) that competitively and reversibly inhibits acid production and secretion. Like other P-CABs, zastaprazan exhibits pharmacodynamic and pharmacokinetic properties that differs significantly from those of PPIs. These differences offer potential advantages, such as rapid, robust, and long-standing acid suppression, the lack of CYP2C19 metabolism, and no need for conversion into an active form. Completed clinical trials of zastaprazan have demonstrated comparable or superior efficacy to that of PPIs for the healing of erosive esophagitis and gastric ulcers without concerning safety signals. Notably, in erosive esophagitis, zastaprazan 20 mg demonstrated faster healing at week 4 compared to esomeprazole 40 mg, whereas in gastric ulcers, zastaprazan 20 mg achieved a 100% healing rate at 8 weeks compared to 97.1% with lansoprazole 30 mg. Zastaprazan is approved in the Republic of Korea for the treatment of erosive esophagitis and gastric ulcer and is undergoing phase III clinical trials for the prevention of non-steroidal anti-inflammatory drug-induced peptic ulcer and the treatment of non-erosive reflux disease. In this review, we summarize and discuss the pharmacology, efficacy, and safety of zastaprazan in acid-related disorders.

Schlagwörter

Stichwörter der Autor:innen

acid-related disordersgastric ulcergastroesophageal reflux diseasepotassium-competitive acid blockerszastaprazan

Autor:innen und Institutionen

  • Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea.
  • Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.

ORCID-Profile: Gwang Ha Kim, Moon Won Lee

Zitieren

APA

Kim, G. H., Joo, D. C., Lee, M. W., & Lee, B. E. (2026). Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders. Journal of Clinical Medicine, 15(10), 3700. https://doi.org/10.3390/jcm15103700

Vancouver

Kim GH, Joo DC, Lee MW, Lee BE. Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders. Journal of Clinical Medicine. 2026;15(10):3700. doi:10.3390/jcm15103700

BibTeX
@article{Kim2026,
  author = {Kim, Gwang Ha and Joo, Dong Chan and Lee, Moon Won and Lee, Bong Eun},
  title = {Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {10},
  pages = {3700},
  doi = {10.3390/jcm15103700}
}
Kostenlos starten →